REFERENCES

1. Longacre TA, Kempson RL, Hendrickson MR. Endometrial hyperplasia, metaplasia and carcinoma. In: Fox H, Wells M, editors. Obstetrical and Gynaecological Pathology. Haines & Taylor, Churchhill Livingstone (4th edition, Vol 1), 1995: 421-510.
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. Cancer 1985; 56:403-12.
3. Clement PB, Scully RE. Endometrial hyperplasia and carcinoma. In: Clement PB, Young RH, editors. Tumours and tumourlike lesions of the uterine corpus. Contemporary issues in surgical pathology (Vol 19). Churchhill Livingstone, 1993: 181-264.
4. Norris HJ, Connor MP, Kurman RJ. Preinvasive lesions of the endometrium. Clin Obstet Gynaecol 1986; 13:725-38.
5. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestin-treated endometrial hyperplasia. Am J Obstet Gynaecol 1989; 160:126-30.
6. Gusberg SB, Kaplan AL. Precursors of corpus cancer. Am J Obstet Gynaecol 1963; 87:662-74.
7. Vellios F. Endometrial hyperplasias, precursors of endometrial carcinoma. Pathol Annual 1972; 201-29.
8. Tavassoli F, Kraus FT. Endometrial lesions in uteri resected for atypical endometrial hyperplasia. Am J Clin Pathol 1978; 70:770-9.
9. Sherman AL, Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynaecol 1979; 135:947-56.
10. Fox H, Buckley CH. The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopath 1982; 6:493-510.
11. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982; 49:2547-59.
12. Hunter JE, Tritz DE, Howell MG, Depriest PD, Gallion HH, Andrews SJ, et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynaecol Oncol 1994; 55:66-71.
13. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynaecol Oncol 1994; 52:373-8.
14. Widra EA, Dunton CJ, McHugh M, Palazzo JP. Endometrial hyperplasia and the risk of carcinoma. Int J Gynaecol Cancer 1995; 5:233-5.
15. Chamlian DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynaecol 1970; 36:659-66.
16. Gronroos M, Salmi TA, Vuento MH, Jalava EA, Tyrkko JE, Maatela JI, et al. Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension. Cancer 1993; 71: 1279-82.
17. Wier HK, Sloan M, Kreiger N. The relationship between cigarette smoking and the risk of endometrial neoplasms. Int J Epidemiol 1994; 23:261-6.
18. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynaecol 1994; 170:1213-23.
19. Cohen I, Tepper R, Rosen DJ, Shapira J, Cordoba M, Dror Y, et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynaecol Oncol 1994; 55:138-43.
20. Silverberg S, Kurman RJ. Endometrial polyps and hyperplasias. In: Tumours of the uterine corpus and gestational trophoblastic disease. Atlas of Tumour Pathology (Vol.3), Armed Forces Institute of Pathology, 1991:15-45.